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Summary
QUESTIONS UNDER STUDY: To compare efficacy and
safety of the dopamine agonist pramipexole (PPX) versus
reference treatment with dual release levodopa/benserazide
(L/B) in de novo patients with restless legs syndrome
(RLS).
METHODS: A total of 39 men and women between 25
and 85 years old, fulfilling all clinical criteria for diagnosis
of idiopathic RLS, previously untreated, participated. The
study was performed as a randomised, double-blind,
double-dummy crossover trial with two treatment periods
of four weeks and took place in six Swiss certified sleep-
centres. Interventions were PPX 0.25–0.75 mg and dual-
release L/B 125–375 mg. The primary outcome measure
was the frequency of periodic limb movements while in
bed (PLM index, PLMI). Secondary endpoints included the
changes in patient ratings on the International RLS Study
Group Rating Scale (IRLS).
RESULTS: Both pramipexole and dual-release L/B were
effective in reducing PLM and RLS symptoms. Mean
PLMI reduction was –11.5 for PPX and –7.7 for L/B
(baseline 21.1 and 21.5), and the mean IRLS score reduc-
tion was –7.2 and –4.0 (baseline 20.8 and 21.1). In pa-
tients with an IRLS score >20 (38%), a significantly (p =
0.047) higher PLMI reduction for PPX (-8.5), as compared
to L/B (–4.3), was found. A higher incidence of “augment-
ations” and “involuntary movements” for L/B, and “naus-
ea or vomiting” and “hypotension with dizziness” for PPX
treatment were noted as adverse effects.
CONCLUSION: This study showed comparable effects of
PPX versus dual-release L/B for short-term treatment of de
novo patients with mild to moderate RLS.
Trial registration number: ClinicalTrials.gov Identifier:
NCT00144209
Key words: restless legs syndrome; periodic limb
movements; pramipexole; dual release levodopa
Introduction
Restless legs syndrome (RLS) is the most common move-
ment disorder and one of the most common sleep-related
disorders with a frequency in the general population
between 2 to 10% [1]. The International RLS Study Group
published an accurate description of diagnostic criteria and
a severity scale for this disorder [2]. Periodic limb move-
ments in sleep (PLMS) occur in about 80% of RLS patients
[3, 4]. The PLMS index (PLM count per hour sleep) or
the PLM index (PLMI), that considers the time spent in
bed (during sleep and wakefulness), and the IRLS are com-
monly used measures to assess the efficacy of a treatment
for RLS. Dopaminergic medications are currently con-
sidered the treatment of choice for RLS [5, 6]. The efficacy
of the dopamine precursor levodopa is well established. Le-
vodopa administered near bedtime was of clear therapeutic
value in treating RLS and PLMS in a series of controlled
trials [7, 8].
Pramipexole (PPX) is a non-ergotamine dopamine agonist
(DA) with selectivity for the D3/2 subtype of the D2 recept-
or family. Previous clinical trials have demonstrated that
PPX is useful in short- and long-term treatment of RLS
[9–12]. To our best knowledge, only two studies compar-
ing the clinical efficacy of levodopa and dopamine agon-
ist therapy in RLS have been reported thus far [13, 14]. In
a double-blind, cross-over randomised 16-day trial includ-
ing 11 patients with idiopathic RLS, pergolide (0.125 mg/
d) was found to be superior to standard levodopa (250 mg/
d) in reduction of both PLMI (as assessed by polysomno-
graphy) and RLS symptoms (as assessed by a simple scale:
complete, nearly complete and no relief) [13]. In a second
double-blind, randomised, active-controlled, parallel-
group, multi-centre 30-week long-term study with 361 pa-
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tients, cabergoline (2–3 mg/d) showed a superior efficacy
over standard levodopa (200–300 mg/d) for reduction of
the IRLS total score [14]. In this second study, standard le-
vodopa was found to be better tolerated than cabergoline
but more often associated with augmentation. The aim of
the present study was to test non-inferiority of PPX in a
head-to-head comparison with dual-release-levodopa (L/B)
in the treatment of RLS by comparing their outcome us-
ing objective measurements, standardised rating scales, as
well as quality of life measures. The choice of the crossov-
er design and of the efficacy endpoints reflects the experi-
ence from earlier studies, where the superiority of both the
control and the test drug against placebo were clearly es-
tablished [9]. The dual release levodopa formulation com-
bines immediate and slow-release levodopa properties and
is commonly used in Switzerland. It was chosen for com-
parison with PPX because of the lower risk of augmenta-
tion in slow release levodopa formulations [8]. Dosages of
PPX and L/B were chosen based upon clinical practice.
Methods
Ethical aspects
The study was reviewed and approved by the Institutional
Review Boards (IRB) and was notified to the Swiss Health
Authority.
Study design
This investigation was performed as a multi-centre, ran-
domised, double-blind, comparative crossover trial (fig. 1)
and was conducted in six certified Swiss sleep-centres
(Zurich, Bern, Basel (2), Zurzach, Lugano).
Patient population
Men and women between 25 and 85 years of age were eli-
gible to participate in the study if they fulfilled all clinic-
al criteria for diagnosis of idiopathic RLS [2]. They had to
present RLS symptoms almost every day, as judged by the
investigator and with more than five PLM/h during bed-
time in each of three consecutive screening nights. All pa-
tients were “de novo” patients with regard to any previous
RLS therapy with PPX, L/B or another DA.
Medication (titration and stable dose period)
PPX 0.25–0.75 mg (Mirapex/Sifrol®) and dual-release L/B
125–375 mg (Madopar® DR) [15] were administered or-
ally, once daily before bedtime.
Tablets for both treatments were packed in identical cap-
sules for blinding. Treatment was started at the lowest dose
Figure 1
Study design: Randomized, double-blind, comparative crossover
study.
(1 capsule), and then adjusted over a period of two weeks
(up to 3 capsules). For further details please see figure 1.
There was no evidence of any carry-over effect.
Data management
Data required for the analysis were recorded and trans-
ferred electronically to a central database by means of
an electronic data capture system (Tri@l-IT, clinIT Ltd,
Freiburg, Germany).
Outcome measures
Overall evaluation of a treatment effect on RLS included an
objective measure of the frequency of periodic leg move-
ments during the time spent in bed(PLM index, PLMI),
as measured by three-night actigraphic recordings (primary
endpoint), and clinical evaluation of the severity of RLS,
using the IRLS rating scale (total change in IRLS score),
and Visual Analogue Scales (VAS) for the assessment of
RLS symptoms as a whole during the day, at sleep onset
and at night [16]. In addition, outcome measures on quality
of life, daytime sleepiness and mood were recorded using
the SF-36 scale, Epworth Sleepiness Scale (ESS) [17],
Hospital Anxiety and Depression Scale (HADS) [18], and
Clinical Global Impression (CGI).
The primary efficacy variable was PLMI, using the PAM-
RL monitor system (IM Systems, Baltimore, USA) [19].
Each of the four series of actigraphic measurements were
obtained over three consecutive nights from both legs. The
analysis only considered the periods when the patient was
in bed with the lights turned off. PLM were analysed auto-
matically and checked visually. Periods with clear artefacts
were excluded from the analysis [20].
Safety was assessed with regard to type and frequency of
adverse events (WHO body system and preferred terms),
including a separate checklist of ten potential adverse drug
reactions (PARS), domperidone needs (overall consump-
tion), laboratory analyses and vital signs.
Statistics
The study followed a two-sequence, two-period crossover
design, and the comparison aimed at providing evidence
for the non-inferiority of PPX with respect to dual release
L/B [21]. The sample size calculation was based on pre-
vious placebo-controlled studies of levodopa and PPX
[10–12]. Based on previous studies we considered a reduc-
tion of the mean PLMI to 10/h or less as being significant.
A sample size of n = 20 patients per group completing the
study (i.e. a total of n = 40 patients) was chosen for this
study. The statistical analyses of the primary and secondary
parameters were based on a per-protocol (PP) population
analysing all patients who completed both treatment peri-
ods. Overall safety was assessed in the intend-to-treat (ITT)
population. The hypothesis of non-inferiority of pramipex-
ole compared to dual release levodopa/benserazide was
tested for PLMI in the per-protocol patient population at
the level α = 2.5%. The analysis was performed using
an ANCOVA-model with the factors treatment, sequence,
subject sequence and period (randomisation) and the
baseline (BL) values as covariate. As the normality distri-
bution assumption for the residuals could not be accepted,
Original article Swiss Med Wkly. 2011;141:w13274
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 2 of 7
a non-parametric crossover test (Wilcoxon rank sums test)
was performed.
In order to incorporate covariates, we used an ANCOVA
model for IRLS. For other secondary parameters an
ANCOVA model (SF 36, CGI), Wilcoxon rank sums test
(VAS, ESS) and exact test (HADS) were used.
Results
Patients
Out of 113 screened patients, 67 were randomised into this
trial (intent-to-treat population). Mainly due to the rigorous
criteria for protocol adherence and strict study drug com-
pliance requests, 28 subjects from these had to be excluded
from the analysis and 39 patients could be included in the
per protocol population. There were 23 females (59%) and
16 males with a mean age of 57 ± 11 (range: 35 to 78). All
of them were of Caucasian origin, and mean body mass in-
dex (BMI) was 25 ± 3 (range: 18 to 34). There was no dif-
ference in drop-out rate due to lack of benefit between the
two groups. A summary of the disposition of randomised
patients is provided in figure 2.
Treatments
Treatment was initiated with one capsule of study drug
(0.25 mg PPX or 100/25 mg L/B). The algorithm for ti-
trating was to increase to 3 capsules per day if needed and
tolerated, and to decrease the number of capsules for side
effects. The recommended time period for any dose adjust-
ments was 3 to 5 days.
Due to insufficient efficacy, the dosage of PPX and L/B
was increased from 1 to 2 capsules at day 3 or 4 in 70% and
78% of the patients, respectively, and again increased to 3
capsules in approximately 50% of all patients at day 7 or 8.
At day 13 to 15, the dosages were reduced in about 10% of
the patients, for L/B (from 3 to 2 capsules) as well as for
PPX (from 2 to 1 capsule). During the maintenance period
(2 weeks) the dosages were kept constant. The mean daily
dosage for PPX was 0.49 mg and for L/B 192/48 mg. The
duration of drug exposure was 29 days for both treatments.
Figure 2
Patient disposition.
Domperidone was administered to 13 patients during treat-
ment with PPX and to 4 patients (safety population) during
treatment with L/B, and the number of tablets ranged from
1 to 5 tablets overall in most cases. Two patients admin-
istered more than 5 tablets during treatment with levodopa
and three patients took more than 5 tablets during
pramipexole treatment. As an outlier, one single patient
took 66 and 59 domperidone tablets during L/B and PPX
treatment periods.
Efficacy
Baseline PLMI scores were comparable between treatment
groups (PP population): Mean values were 21.5 (SD 14.9)
for PPX and 21.1 (SD 17.0) for L/B. Combining both study
periods, the PLM index at week 4 showed mean (SD) val-
ues for PPX and L/B of 10.0 (10.9) and 13.4 (12.8), result-
ing in a mean reduction of 11.5 (13.9) and 7.7 (9.5) respect-
ively (table 1). Comparing reduction from baseline PPX
was non-inferior in comparison to L/B on the primary end-
point PLMI (p = 0.00015).
Baseline IRLS scores were comparable between treatment
groups; 20.8 (8.2) for PPX and 21.1 (6.9) for L/B. Combin-
ing both study periods, the IRLS score at week 4 exhibited
a mean reduction from baseline of 7.2 (9.5) and 4.0 (7.5),
respectively. Statistical analysis of the treatment effect us-
ing an ANCOVA model revealed a p-value of 0.054 and
indicated a trend in favour of PPX. A baseline IRLS score
≤20 was found in 18% of the patients, 44% were “mixed”
(one score ≤20, one score >20), and 38% had an IRLS
score >20. The subgroup analysis in patients with IRLS
score >20 (severe to very severe) at baseline showed a sig-
nificantly (p = 0.047) greater reduction of IRLS score at
week 4 for PPX (8.5 (7.7)) as compared to L/B (4.3 (5.4)),
shown in table 1, together with median and ranges.
An additional exploratory analysis performed to investigate
any potential correlation between PLMI and total IRLS
score at baseline and end of treatment and between the
corresponding changes, revealed correlation factors of
–0.0937 (baseline), 0.0538 (end) and 0.0566 (change), re-
spectively, indicating no correlation between PLMI and
total IRLS score.
Comparison of RLS symptoms by means of VAS (100 mil-
limetre scale) during different phases of the day revealed
different changes (SD) under PPX compared to L/B treat-
ment: During the day –8.5 (18.7) versus +1.8 (23.3) with a
trend in favour of PPX (p = 0.05), at sleep onset –9.3 (25.4)
versus –8.6 (32.1) with p = 0.67, and during the night –14.1
(32.4) versus –18.5 (28.3) with p = 0.65. For results on the
other secondary efficacy parameters see table 1.
Safety
Analysing the safety population (67 patients), 87 adverse
drug reactions (ADR) were observed during L/B (39 pa-
tients) and 116 ADR were observed during PPX treatment
(38 patients). For PPX, a higher incidence of nausea (31%),
headache (17%), constipation (9%) and vomiting (8%) was
observed compared to L/B treatment (17%, 11%, 5% and
3%, respectively). For L/B, a higher number of events as-
sociated with RLS syndrome (22%) and dizziness (17%)
was recorded compared to PPX treatment (9% and 13%).
The incidence of nightmares was more frequent with PPX
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compared to L/B treatment (6% and 3%, respectively). In
the other organ system classes, adverse events showed a
comparably low incidence for both treatment groups. No
serious adverse event occurred during the treatment peri-
ods. One adverse event occurred in the PPX group, and was
classified as significant, described as a “short absence dur-
ing car driving” assigned to the preferred term “sleep at-
tack”, and judged by the investigator as not related.
Results of the potential adverse reactions (PARS) checklist
are shown in table 2.
The majority of patients had clinical laboratory values and
vital sign within normal range, clinically acceptable ranges,
or with values essentially unchanged between baseline and
end of study measurements.
Table 1: Treatment effects on primary and secondary outcome measures in PP population (n = 39).
L/B PPX
Baseline Week 4 Baseline Week 4
PLMI
Mean (SD)
Median (Range)
Change from Baseline
Mean (SD)
21.1 (17.0)
14.4 (1.6–69.5)
13.4 (12.8)
10.1 (0.5–49.3)
–7.7 (9.5)
21.5 (14.9)
18.5 (1.5–55.2)
10.0 (10.9)
5.4 (0.4–45.0)
–11.5 (13.9)
IRLS score
Mean (SD)
Median (Range)
Change from Baseline
Mean (SD)
21.1 (6.9)
22 (7–35)
17.1 (7.8)
19 (1–30)
–4.0 (7.5)
20.8 (8.2)
22 (6–37)
13.6 (8.0)
14 (0–31)
–7.2 (9.5)
IRLS scores >20 “severe and very severe” (n = 15)
Mean (SD)
Median (Range)
Change from Baseline
Mean (SD)
26.5 (4.3)
27 (21 to 35)
22.3 (4.3)
23 (10–27)
–4.3 (5.4)
26.3 (3.8)
25 (22–37)
17.8 (7.7)
19 (0–31)
–8.5 (7.7)*
Epworth Sleepiness Scale (ESS)
Mean (SD)
Median (Range)
8.7 (3.7)
9 (3–16)
8.2 (3.7)
8 (2–18)
8.2 (4.0)
8 (1–17)
7.9 (3.4)
8 (2–17)
Quality of Life (SF-36)
Physical component
Mean (SD)
Median (Range)
Mental Component
Mean (SD)
Median (Range)
44.9 (5.3)
45.1(33.0–60.3)
42.2 (6.0)
43.1(20.4–49.4)
45.0 (5.5)
44.4 (25.5–58.4)
42.5 (6.5)
44.8(20.8–53.0)
44.8 (5.2)
44.6(32.3–57.6)
42.5 (6.0)
44.2(26.3–51.1)
43.5 (4.8)
43.5 (34.4–54.0)
43.1 (5.4)
44.1(25.6–52.9)
Hospital Anxiety and Depression Score (HADS)
Anxiety score
Mean (SD)
Median (Range)
Depression score
Mean (SD)
Median (Range)
8.3 (2.4)
8.0 (3–17)
11.2 (1.6)
11.0 (7–14)
8.3 (1.8)
8.0 (5–13)
11.2 (1.9)
12.0 (6–15)
8.6 (2.2)
8.0 (4–15)
11.4 (1.4)
11.5 (9–14)
8.0 (1.6)
8.0 (5–12)
11.6 (1.4)
12.0 (8–15)
Statistics: PLMI: No carry-over effect and no period effect were observed. The difference in PLM index was not significant (p = 0.065). IRLS-Score: Treatment effect was
p = 0.054. Subpopulation severity “low to moderate” was p = 0.68 and “severe to very severe” was p = 0.047*.
Table 2: Total number of Potential Adverse Drug Reactions (PARS) in PP population (n = 39).
L/B PPX
PARS BL Week 2 Week 4 BL Week 2 Week 4
Asthenia 11 6 5 8 8 8
Augmentation* 0 8 7 0 3 2
Constipation 5 4 5 3 9 7
Oedema 1 0 1 3 2 3
Hallucinations or visual disturbances 1 3 2 1 2 4
Hypotension with dizziness 1 9 7 6 11 9
Involuntary movements 12 9 10 15 7 7
Nausea or vomiting 0 9 4 4 20 10
Rebound** 7 4 3 1 2 3
Sleep attacks*** 1 0 0 0 0 0
Other adverse event(s) 7 29 16 3 21 18
Total 46 77 60 44 85 71
* Augmentation: Increased intensity of RLS symptoms OR shorter onset time OR involvement of the other limb.
** Rebound: RLS symptoms in the early morning.
*** Sleep attack: Falling asleep, possibly without warning signs, during “active” activities, such as eating, driving a car or making a phone call.
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Discussion
The Swiss RLS study is the first investigation directly com-
paring a non-ergot dopamine agonist with levodopa in a
crossover design and overall is the third head-to-head study
in RLS. The choice of PLMI as the primary endpoint re-
flected the standard approach at the time the study was
planned. In addition, PLM actigraphy is an objective as-
sessment of leg motor activity. The IRLS score – one of the
secondary endpoints in the current study – is currently the
preferred endpoint in large-scale RLS trials. The absence
of a significant correlation between PLMS and IRLS in this
and in previous studies, underscore however the utility of
assessing both variables in RLS treatment studies [10, 20,
22, 23].
The current study proves that PPX (mean dose of 0.49
mg/d) and dual release L/B (mean dose of 192/48 mg/
d) are comparably effective in the treatment of de novo
RLS patients. A significantly greater reduction of the IRLS
score in the subpopulation “severe and very severe” (p =
0.047) was found with PPX when compared to dual release
L/B. The overall improvement of both PLMS and IRLS
was relatively modest, although comparable with data from
other studies referring to a 6-week administration of per-
golide [22], a 4-week administration of ropinirole [23] and
a 12-week treatment with pramipexole [24]. The limited
improvement of PLMS/RLS may be related to different
factors. Firstly, only de novo patients were included, and
secondly, only 38% of our patients had a baseline IRLS
>20. Most recently published large-scale treatment studies
in RLS included patients with mostly moderate-severe dis-
ease and only few de novo patients [14, 22, 23, 25].
Baseline evaluations of the other secondary efficacy para-
meters including quality of life, ESS and HADS scores re-
flected moderate disease characteristics, and as a conse-
quence changes at week 4 were of minor magnitude.
Overall, treatment with PPX and dual release L/B was well
tolerated; the overall frequency of AEs was similar. No
severe AEs assigned to treatment intervals occurred, and
only one significant AE was reported. The vast majority of
clinical laboratory parameters and vital signs were within
normal ranges. Treatment-emerged adverse drug reactions
were observed in 59% and 61% of the patients during PPX
and L/B treatment, respectively and were comparable with
results of studies with pergolide (67%), ropinirole (45%)
and cabergoline (55–67%) [22, 23, 26]. During treatment
with L/B more patients reported restless legs symptoms
(22%) and dizziness (17%). The incidence of nausea with
PPX reported in this study was higher (31%) compared to
results with PPX in other studies (15% and 19%) [12, 24].
This may in part be related to the higher initial dose of 0.25
mg, compared to the usual starting dose of 0.125 mg, but
also to the short titration time from 0.25 mg to 0.75 mg
in two steps within 7 to 8 days. The higher incidence and
severity of the reported PARS “augmentation” associated
with the comparator drug is a well documented effect of
L/B, although a treatment duration of 4 weeks may be too
short to assess this complication [26, 27].
In conclusion, this study demonstrates pramipexole and
dual-release levodopa to be comparably effective in the
short-term treatment of patients with mild to moderate
idiopathic RLS.
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Figure 1
Study design: Randomized, double-blind, comparative crossover study.
Figure 2
Patient disposition.
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